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with ICD-9 diagnosis codes for stroke/TIA had their diagnostic imaging utilization 
summarized within ±3 days of the stroke/TIA event. Results: A total of 18,770 
matched patients were identified; average age 65.5 (13.38 SD) and 21.9% female. 
When comparing patients that had at least one diagnostic procedure within the 
year, ICD patients had significantly less imaging overall [5.4 (6.38 SD) vs. 6.8 (8.18 
SD), p< 0.0001]. Among patients with records of stroke/TIA (ICD 5%, non-implant 
4%) and accompanying diagnostic imaging, 44% of non-implant patients underwent 
magnetic resonance imaging (MRI) vs. 1% of ICD patients (p< 0.0001) and had more 
imaging tests overall (4.1 (2.47 SD) vs. 3.2 (2.16 SD), p< 0.0001). ConClusions: MRI 
utilization is lower in ICD patients compared to non-implant patients. One in 20 ICD 
patients require imaging for a recorded stroke/TIA and less than 1% received MRI 
for this indication. The burden of incident stroke/TIA in contemporary ICD patients 
may justify consideration of MRI conditional devices in the majority of ICD patients.
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objeCtives: This study aimed to compare and evaluate the health-related quality of 
life (HRQOL) in Asian end-stage renal disease (ESRD) patients treated with continu-
ous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) 
in Singapore. Methods: Data used in this study were from two cross-sectional 
surveys conducted between 2009 and 2013. Participants were recruited from the 
PD centers of Singapore General Hospital and National University Hospital. The 
inclusion criteria were ESRD patients who have been on PD for at least 3 months 
and at least 21-year-old. In both surveys, participants completed the Kidney Disease 
Quality of Life (KDQOL) instrument and questions assessing socio-demographic 
characteristics. Co-morbidities, clinical, and dialysis-related variables (i.e. vintage, 
dialysis adequacy, dependency status [self-cared/assisted]) were retrieved from 
medical records. The 36-item KDQOL (KDQOL-36) was used to generate two generic 
summary scores (physical component summary [PCS], mental component sum-
mary [MCS]), three disease-specific scales (symptoms, effects, burden), and two 
health utility scores (Short Form 6-Dimension [SF-6D] and EuroQol 5-Dimension 
[EQ-5D]). The HRQOL of patients treated with CAPD and APD measured by the above-
mentioned scales was compared using separate linear regression models with 
and without adjustment of variables collected. Results: Of the 382 PD patients 
approached, 266 were eligible and agreed to participate: 145 on CAPD (mean age: 60.8 
years; female: 54.5%) and 121 on APD (mean age: 57.4 years; female: 54.5%). Without 
adjustment, the HRQOL of CAPD and APD patients were similar according to all 
measures except for KDQOL symptoms (difference: 6.2, p< 0.01). With adjustments, 
significant differences were observed in KDQOL symptoms (7.0, p< 0.01) and PCS 
(2.8, p< 0.05) between CAPD and APD patients, suggesting that APD was associated 
with milder dialysis-related symptoms and better physical health. ConClusions: 
It appears that APD patients experience better HRQOL in some domains than CAPD 
patients in Singapore, although generic utility measures are not sensitive to this 
treatment advantage.
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objeCtives: This study aimed at assessing patient preferences for different char-
acteristics of Dry Powder Inhalers (DPIs) from patients with asthma and chronic 
obstructive pulmonary (COPD) disease in France. Methods: Attributes character-
izing DPIs and attribute levels were defined using focus groups among asthma and 
COPD patients and interviews of health care professionals, previously reported. 
Those attributes were ease of use, accurate and easy-to-read dose counter, dose 
confirmation, hygiene of the mouthpiece, flexibility of device handling and use with 
breathing difficulties. A survey was conducted among asthma and COPD patients to 
elicit patients’ preferences and willingness to pay using the discrete choice experi-
ment (DCE) method. A fractional factorial design including 3 sets of 12 choices was 
created. Each choice was made in two steps: a choice between two fictitious inhal-
ers then between preferred inhaler and current inhaler. Analyses were performed 
using a ranked ordered logit model. Interactions between attributes and asthma/
COPD were tested. Results: Participants included 201 patients with asthma and 60 
with COPD. Asthma patients were on average 40 years old and COPD patients were 
51 year old. Patients were willing to pay € 4.70 per month (standard error: € 0.49) for 
an inhaler requiring one step to prepare a dose instead of four, € 3.62 (€ 0.61) for an 
accurate dose counter compared to a less precise one, € 3.27 (€ 0.48) for an inhaler 
giving confirmation that the dose has been taken, € 1.02 (€ 0.38) for flexibility of han-
dling and € 4.79 (€ 0.73) to be able to use the inhaler in case of breathing difficulties. 
Preferences of patients with asthma and COPD are largely similar. ConClusions: 
Patients with asthma and COPD place highest values on the ease of use and abil-
effective. Screening of other immunocompromised populations is cost-prohibitive, 
however with minimal well-designed studies using consistent assumptions and 
parameters, these Conclusions should be interpreted cautiously.
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objeCtives: To estimate the cost attributed to productivity loss due to patient’s 
hospitalization, in patients subjected to pacemaker (PM) and implantable cardi-
overter-defibrillator (ICD) implantation. Methods: A single-center, prospective, 
cost-of-illness study was conducted for one year period. In total, 464 consecutive 
patients were recruited. 370 were subjected to PM implantation, (240 initials, 130 
replacements) and 94 to ICD (80 initials, 14 replacements). Data were assessed at 
patients’ enrolment in the study and at 6th and 12th months after the implanta-
tion. Then, the cost attributed to productivity loss due to patient’s hospitalization, 
was calculated using a bottom-up approach. Results: The mean (95% confidence 
interval) cost attributed to productivity loss for the PM recipients was found to be 
€ 39 (€ 25–€ 53). € 43 (€ 26–€ 64) for the patients who were subjected to initial implanta-
tion and € 30 (€ 12–€ 57) for the patients subjected to replacement. In one year follow 
up for the patients who were subjected to PM implantation the mean cost was € 71 
(€ 70–€ 72), € 71 (€ 70–€ 73) for the patients who were subjected to initial implantation 
and € 70 (€ 70–€ 70) for the patients subjected to replacement. For the ICD recipi-
ents was found to be € 186 (€ 119–€ 268), € 207 (€ 130–€ 303) for the patients who were 
subjected to initial implantation and € 53 (€ 0–€ 140) for the patients who were 
subjected to replacement. In one year follow up for ICD recipients the mean cost 
was € 367 (€ 72–€ 802), € 414 (€ 73–€ 926) for the patients who were subjected to initial 
implantation and € 70 (€ 70–€ 70) for the patients who were subjected to replace-
ment. ConClusions: The study provides unique data regarding the cost attrib-
uted to productivity loss of CRMD recipients in Greece. The mean cost attributed to 
productivity loss, in the case of ICD recipients is much higher than in PM recipients.
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objeCtives: Advances in ultrasound technology and training have made it possible 
for physicians to conduct detailed imaging studies in an office setting. Ultrasound 
images make it possible to visualize subclinical evidence of disease activity quickly 
and could contribute to prompt initiation of therapy in patients with rheumatoid 
arthritis (RA). The objectives of this study were to describe the use and cost of 
ultrasound in patients with a confirmed diagnosis of RA, in the United States, over 
the last decade. Methods: Patients were selected from a large national private 
insurance-claims database if they had at least 2 claims for ICD-9 code 714.xx at 
least 45 days apart and received Disease-Modifying Antirheumatic Drug therapy 
between 2002 and 2013. The CPT codes 7880-7882 were used to identify ultrasound 
procedures. Descriptive statistics were used and simple hypothesis tests per-
formed. Results: A cohort of 129,005 patients with RA was selected for this study. 
Patients who received ultrasounds were significantly (p < 0.01) more likely to be 
younger, female, have point-of-service insurance, and live outside the Midwest. 
Between 2002 and 2013, there was a > 1900% increase in the use of ultrasound in 
this patient population, from 73 procedures in 2002 to 1448 procedures in 2013. 
During this same period, the mean cost of the ultrasound procedure fluctuated 
over time; the cost increased 35% to a high of $216 (2013 USD) in 2008 and then 
decreased starting after 2010 down 32% by 2013 to $146 (2013 USD). Rheumatologists 
performed 70% of the procedures. ConClusions: This research clearly shows that 
use of ultrasound, primarily by rheumatologists, has been increasing. The data also 
show that patients who received ultrasounds may be different than those who did 
not receive the procedure. Further research is needed to evaluate the impact ultra-
sounds may have on treatment decisions, access to biologics, and patient outcomes.
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objeCtives: We examined diagnostic imaging utilization across all medical 
conditions and in the case of acute stroke in patients with implantable cardio-
verter defibrillators (ICD) and a propensity matched cohort without record of any 
devices. Methods: This study used data from MarketScan® Commercial Claims 
and Medicare Supplemental database (Truven Health Analytics, New York, NY). 
Patients with continuous health plan enrollment in the calendar year 2012 with 
and without ICDs were identified. Patients in the ICD group were matched 1:1 using 
direct (age, gender and type of insurance plan) and propensity score matching 
(comorbid conditions) to patients with no record of device implantation. Diagnostic 
imaging utilization was compared across the matched cohorts, in total and by imag-
ing category, for the calendar year 2012. The same comparison was carried out 
for the stoke/TIA sub-population of interest. For the calendar year 2012, patients 
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TKA surgery (95% CI: 1.095-1.356). Patients concerned about experiencing pain (first 
several weeks following surgery) had significantly higher odds of delaying surgery 
(OR: 1.64, 95% CI: 0.881-3.06). 92% of survey respondents indicated they would seek 
surgeons who offered an effective non-opiate pain management option during the 
rehabilitation period. Gender, income level, and education level were not significant 
factors in the decision to delay TKA surgery. ConClusions: In a relatively wealthy, 
well-educated US-based population, the decision to delay a TKA is significantly 
influenced by patient concerns about interference with work and experiencing pain 
following TKA. Non-opioid pain management is important in selecting a surgeon.
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objeCtives: Despite numerous studies highlighting the importance of HbA1c con-
trol, literature quantifying the marginal effect of self-monitoring of blood glucose 
(SMBG) on HbA1c control is somewhat limited. Recognizing this knowledge gap, 
this study assessed the association between increased use of testing strips and 
glycemic control, taking into account insulin regimen, type I/II status, and other 
patient-level characteristics. Methods: Patient inclusion and exclusion criteria 
were adapted from HEDIS Comprehensive Diabetes Care guidelines. Commercially 
enrolled patients on insulin regimen (basal, bolus, or pre-mixed) with at least 
one diabetic strip fill between the ages of 18 to 75 years were identified from the 
HealthCore Integrated Research Database®. Continuous enrollment for 12 months 
pre/post the earliest testing strip fill (‘index’) was required. Clinical outcome was 
defined as most current HbA1c lab value within 1 year post-index period. Using 
average marginal effects (AME) analysis with bootstrapping, we estimated the like-
lihood of patient’s control (HbA1c < 8.0%) as number of testing strip fills increased, 
adjusting for age, gender, insulin regimen, and other variables. Results: Within 
this population, 45.8% of patients were unable to achieve control rates of < 8% dur-
ing the study period. However, patients with higher fill rates (> = 4 fills) were more 
likely to achieve control (60.9%) relative to a 44.0% control rate among those with 
low fill rates (< 4 fills). Using the AME analysis, each increase in fills was associ-
ated with a 2.5% increase in achieving control (AME: 2.5%, 95% C.I.: 2.1% - 2.8%, 
p< .001). The marginal effect between strip fills and HbA1c control was greater 
among type I patients (AME: 3.5%, 95% C.I.: 2.5% – 3.5%, p< .001). ConClusions: 
We found a statistically significant AME between testing strip fills and glucose 
control. These findings highlight the importance of efforts to encourage better 
SMBG among patients on insulin, with implications for improved patient outcomes 
and long term cost savings.
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objeCtives: Healthcare in the US is being reimagined to deliver technology enabled, 
high quality, cost-effective care. User experience (UX) drives clinician preferences 
and outcomes, while both clinical and economic impact drives payer/purchaser 
preferences. Elements of user experience include ease of use, reproducibility of 
results, and ability to easily and effectively understand directions and interfaces. 
All of which impact safety, reliability, and reproducibility- metrics important to 
payers. Methods: Data from 5 payer/purchaser studies of medical devices were 
reviewed to characterize the intersection of value drivers and impact variables. 
Expert evaluation techniques (Zhang 2003) were applied to identify key features that 
have an effect on both usability and predicted value. Results: Across studies, the 
usability of devices were tied to factors that impact clinical or cost-outcomes, but 
are not considered by payers and other purchasing groups routinely. Specifically, 
physician and patient preferences on usability criteria impacts error rates, proce-
dure time, patient satisfaction, and adherence. ConClusions: User experience 
criteria need to be embedded within value analyses by payers and purchasers to 
ensure technology innovations are optimized to deliver value along clinical and cost 
dimensions. This evaluation dimension helps further align coverage and purchasing 
decisions with quality incentives.
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objeCtives: Digital health solutions are an emerging trend in healthcare delivery, 
with over $3 Billion dollars being invested in the space in the first three quarters of 
2014 alone, surpassing total medical device venture funding and representing 100% 
YoY growth. Healthcare, technology, and industry stakeholders are collaborating to 
develop tools that provide near patient monitoring, engagement, and interaction 
with providers with the expectation that these technologies will improve care and 
potentially decrease costs. However, little work has been done to develop methods 
to evaluate digital health solutions for payers and HTA decision-makers. The objec-
tive of this study was to determine the framework with which US payers will make 
coverage decisions for digital health technologies. Methods: In-depth interviews 
were conducted with 15 US payer and HTA decision-makers to determine prefer-
ences for evaluation frameworks for digital health technologies, drivers of value, 
evidence requirements, and economic impact expectations. Results: Most payers 
reported that they were currently experimenting with digital health technologies 
ity to use the inhaler in case of breathing difficulties, followed by features giving 
patients the reassurance about taken dose – precise dose counter and confirmation 
mechanism.
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objeCtives: Prevalence of neuropathic pain in patients with chronic low back pain is 
high. Screening for neuropathic pain is important because pharmacological manage-
ment differs from nociceptive pain. There are various methods to assess the neuro-
pathic pain. However these methods have shown different sensitivity and specificity 
in identifying the neuropathic pain. Present study compared the IASP grading system 
and S-LANSS in identification of neuropathic pain in patients with chronic low back 
pain. Methods: This is a prospective questionnaire based study where consecu-
tive chronic low back patients attending pain clinic of public tertiary care teaching 
hospital was included for the study. Each patient was examined by the physician 
and graded according to the IASP grading system about the certainty of neuropathic 
pain. Later patients ﬁlled the S-LANSS Questionnaire. Results: According to the 
IASP grading system, 45 patients (75%) classiﬁed as probable or deﬁnite neuropathic 
pain and 15 patients (25%) as unlikely neuropathic pain. According to the S-LANSS 
Questionnaire, 30 patients (50%) were classiﬁed as likely neuropathic pain and 30 
patients (50%) as unlikely neuropathic pain. All patients who were classiﬁed as neu-
ropathic pain according to S-LANSS questionnaire were also classiﬁed as deﬁnite or 
probable neuropathic pain by the IASP grading system. ConClusions: About 25% of 
neuropathic pain patients were not detected by S-LANSS. Self reported neuropathic 
pain assessment scale may miss patients with neuropathic pain.
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objeCtives: Various assessment instruments are used for gathering data on 
different functional domains (i.e., mental), from various reporters (e.g., patient 
or observer). The objective of this study was to create an inventory of functional 
instruments used in patients with cognitive impairment and to categorize them 
using a taxonomy that combines several approaches: functional domain, data 
reporter, and performance versus opinion based. Methods: A literature search 
was conducted using the following: English language, any date, “performance based 
measure”, “performance measures”, “performance tests”, “cognitive function tests”, 
“functional measures”, “functional tests”, “cognitive measures”, “functional assess-
ment”, “cognitive impairment”, “Alzheimer’s disease”. Three reviewers abstracted 
and evaluated retrieved studies to identify measure instruments and assign catego-
ries: 1. Addressing physical, mental, and/or social functioning; 2. Performance based 
(PerfO) or opinion based; and 3) Patient-reported (PRO), clinician-reported (ClinRO), 
or observer reported (ObsRO) outcome. Discrepancies among reviewers were decided 
through consensus. Results: The literature search led to the identification of 212 
measures used in cognitive impairment. Reviewers identified 134 as PerfOs. The 
remaining 78 opinion-based measures were categorized into PROs, ClinROs, and 
ObsROs. Overall, one, 17, and 152 measures assessed social, physical, and mental 
functioning, respectively. Forty-two measures assessed multiple domains. Within 
the 134 PerfOs, 13 were designed to assess physical, 109 mental, and one social 
functioning. Eleven included multiple functional domains. ConClusions: When 
measuring function in patients with cognitive impairment, it is important to rec-
ognize the wide range of instruments available and their characteristics. The tax-
onomy applied here, organizing functional-measure instruments used in cognitively 
impaired populations by various characteristics, is recommended as a starting point 
for characterizing tools. Researchers and clinicians can use such an approach to 
better understand the complexity of the measures as well as the strengths and 
limitations of these tools to guide them in selection and use, and interpretation 
of findings.
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objeCtives: Delaying a total knee arthroplasty (TKA) carries an increased likeli-
hood of poor rehabilitation outcomes. TKA candidates may choose to delay surgery 
for a variety of reasons including perceptions of pain and interference with activi-
ties due to pain. This study explores patients’ perspectives and factors related to 
the decision to delay a TKA procedure. Methods: Cross-sectional online survey 
conducted among U.S. patients with arthritis who were candidates for TKA. Survey 
questions related to pain severity and activity interference due to pain were taken 
from the Brief Pain Inventory (BPI); additional questions were related to pain man-
agement, the decision to delay TKA surgery and demographic information. Data was 
analyzed using descriptive statistics and logistic regression using SAS 9.3. Results: 
There were 654 respondents; mean age 64±7 years; 65.5% female; 62% with house-
hold income ≥ $50,000; 55.4% with bachelor or graduate degree. Logistic regression 
showed that interference with work and concerns for pain (pain in the first 3 days 
or pain in the first several weeks following surgery) were significant in predicting 
the decision to delay knee replacement surgery. A one unit increase in the interfer-
ence with work scale is associated with a 21.9% increase in the odds of delaying 
